BioMark Diagnostics, Inc. · CSE:BUX

BioMark Diagnostics — Investor Presentation (May 2021)

26 slides from BioMark Diagnostics's investor presentation, May 2021

  1. Slide 1: A Next Generation Company Powered by Metabolomics and Artificial Intelligence

    Slide 1: A Next Generation Company Powered by Metabolomics and Artificial Intelligence

    A NEXT GENERATION COMPANY POWERED BY METABOLOMICS AND ARTIFICIAL INTELLIGENCE

  2. Slide 2: Our Mission / Who We Are

    Slide 2: Our Mission / Who We Are

    Our Mission Who We Are Provide better cancer detection, • Developer of a pan cancer liquid biopsy monitoring and screening solutions for platform company with advanced near-to- hard to detect cancers market diagnostic technologies. • Multiple IP’s in detection and quantitation of metabolites. • Hand

  3. Slide 3: BioMark Executive Team & Advisors

    Slide 3: BioMark Executive Team & Advisors

    BioMark Executive Team & Advisors Rashid Ahmed Bux, MBA Gina Huang, MBA Dr. Bram Ramjiawan, Ph.D Brian Cheng, MSc Founder, Chief Executive Officer CFO and Project Director Clinical Trial and Regulatory Expertise Chief Technical Officer Mr. Alfred Berkeley – Strategic and financial advisor Dr. David

  4. Slide 4: BioMark Corporate Structure

    Slide 4: BioMark Corporate Structure

    BioMark Corporate Structure 4

  5. Slide 5: Partners & Associations

    Slide 5: Partners & Associations

    Partners & Associations Institutions = U of Maryland; Johns Hopkins; Government – CIHR; CHRP; NSERC; Mt Sinai; IUCPQ; University of Manitoba; Genome BC; Canadian Cancer Society University of Alberta; UBC; University of Brescia; Université Laval Japanese based technology company Biopharma – 2 NDAs CR

  6. Slide 6: Value Proposition - Actionable Diagnostic Test

    Slide 6: Value Proposition - Actionable Diagnostic Test

    VALUE PROPOSITION- ACTIONABLE DIAGNOSTIC TEST Our technology solution – offers • Early diagnosis and screening – Application in screening for late, aggressive and hard to detect cancers such as lung and Physician Patient brain cancers. These cancers have clearly identified populations. • Effective m

  7. Slide 7: Empowering Oncologists

    Slide 7: Empowering Oncologists

    EMPOWERING ONCOLOGISTS novel technologies for CANCER SCREENING EARLY DETECTION

  8. Slide 8: Lung Cancer – The Big Picture

    Slide 8: Lung Cancer – The Big Picture

    Lung Cancer – The Big Picture Lung cancer has been the most common cancer in the world for several decades and accounts for 1 in 5 of all cancer deaths. Worldwide, three people die from lung cancer every minute More than 2/3rds of patients are diagnosed with lung cancer at a later stage when their s

  9. Slide 9: 5 Year Relative Survival Rates (%)

    Slide 9: 5 Year Relative Survival Rates (%)

    5 Year Relative Survival Rates (%) Importance of Stage Shifting – Early Detection is Critical to Save Lives STAGE LUNG (NSCLC) BREAST PANCREATIC 1A 92 100 37 1B 68 2A 60 93 12 2B 53 3A 36 72 3 3B 26 4 10 22 9

  10. Slide 10: Lung Cancer Market Highlights

    Slide 10: Lung Cancer Market Highlights

    Lung Cancer Market Highlights Commercialization Roadmap Target - Lung Cancer Screening in US for identified high risk groups to complement LDCT Scan Estimated Population Size : 16 million Current Uptake 3%; 18% cancers detected are indolent; BioMark over diagnosis Imaging is used for Screening – Low

  11. Slide 11: BioMark's Lung Cancer Solution

    Slide 11: BioMark's Lung Cancer Solution

    BioMark’s Lung Cancer Solution Commercialization Roadmap Solution: Use BioMark’s assay that is cost effective and can potentially reduce false positives and negatives associated with LDCT Scans. (reduce and manage diagnostic dilemma) – rule in /out Can use as routine test Following patients with abn

  12. Slide 12: Technology Platform & Product Pipeline

    Slide 12: Technology Platform & Product Pipeline

    Technology Platform & Product Pipeline Planning Development Validation Regulatory Approval Market Internal Standards developed and data points SSAT-Amantadine Assay using LC/MS –Pan Cancer collected and to be validated. Collaboration with an IVD kit manufacturer begin SSAT-Amantadine Assay using ELI

  13. Slide 13: Discovery & Development of Liquid Biopsy Assays

    Slide 13: Discovery & Development of Liquid Biopsy Assays

    Discovery & Development of Liquid Biopsy Assays Completed development and validation of 2 metabolomic assays – Platform Play Pan Cancer Acetyl Amantadine Assay (SSAT 1) Multi Panel Biomarkers – First Application Use of an FDA Approved Drug As A Tracer Lung Cancer Based on key discovery by Dr. Sitar

  14. Slide 14: Assay I

    Slide 14: Assay I

    Assay I Pan Cancer Acetyl Amantadine Assay (SSAT 1) 14

  15. Slide 15: Convenient & Non-Invasive

    Slide 15: Convenient & Non-Invasive

    Convenient & Non-Invasive SSAT 1 AMANTADINE ASSAY Amantadine + 2 – 4 Hours Water Labs Collect Biological Sample (Urine or Blood) Reference Labs Point of Care Analyze and Confirm Physician Facility or Home (Urine) Physician Report 15

  16. Slide 16: Current SSAT1 Amantadine/Rimantadine Assay Activities

    Slide 16: Current SSAT1 Amantadine/Rimantadine Assay Activities

    Current SSAT1 Amantadine/Rimantadine Assay Activities Phase III Clinical Trial Use of SSAT 1 Clinical Trial Response to Chemo & Radio For GBM Therapy for Lung Cancer* Urinary Excretion of CancerCare Manitoba The use of SSAT 1 based Acetylamantadine by Cancer biomarkers to assess surgical Patients He

  17. Slide 17: Measuring Response to Treatment for Lung Cancer Using SSAT Assay

    Slide 17: Measuring Response to Treatment for Lung Cancer Using SSAT Assay

    Measuring Response to Treatment for Lung Cancer Using SSAT Assay MARKET FOCUS: BioMark’s assay will be used to predict response and outcome of systemic therapy for patients on chemotherapy, immunotherapy and radiotherapy treatment. How ? Determine concurrence to SSAT1 concentration in urine or plasm

  18. Slide 18: Application Leveraging of SSAT Assay – Glioblastoma Market

    Slide 18: Application Leveraging of SSAT Assay – Glioblastoma Market

    Application Leveraging of SSAT Assay – Glioblastoma(GBM) Market Activities and Potential Outcomes Our Value Proposition - Develop better diagnostic tools to assess Glioblastoma is the most common primary malignant form of brain progression and response to treatment. No paradigm shift for many cancer

  19. Slide 19: Assay II

    Slide 19: Assay II

    Assay II Targeted BioMarker Panel for Early Detection of Lung Cancer Using Liquid Biopsy 19

  20. Slide 20: Targeted Metabolomics Lung Cancer Trials

    Slide 20: Targeted Metabolomics Lung Cancer Trials

    Targeted Metabolomics Lung Cancer Trials Data Summary Total Subjects: 257 Metabolomics Analysis: Human plasma samples* were analyzed using custom developed assay for several Normal: 60 putative lung cancer biomarkers. Lung Cancer: 197 (emphasis on Stages 1 and 2) *Samples and data obtained from IUCP

  21. Slide 21: Results: Strong AUROC For Early-Stage Detection

    Slide 21: Results: Strong AUROC For Early-Stage Detection

    Results: Strong AUROC For Early-Stage Detection PERFORMANCE OF LOGISTIC REGRESSION PERFORMANCE OF LOGISTIC REGRESSION MODEL A MODEL B AUC SENSITIVITY SPECIFICITY AUC SENSITIVITY SPECIFICITY TRAINING/ 0.974 (0.965 ~ 0.937 (0.920 ~ 0.922 (0.895 ~ TRAINING/ 0.982 (0.975 ~ 0.960 (0.946 ~ 0.944 (0.921 ~

  22. Slide 22: Next Commercialization Steps for Early Lung Cancer Detection

    Slide 22: Next Commercialization Steps for Early Lung Cancer Detection

    Next Commercialization Steps for Early Lung Cancer Detection • Sponsored Lung Cancer Trial • Assemble a pan Canadian multidisciplinary team of experts • Source samples from IUCPQ Biobank - (1500 samples) • Timing: April- July 2021 • Set up lab in Quebec for sample analysis -2nd. Quarter 2021 22

  23. Slide 23: Projected Lung Cancer Market Entry & Revenue Model

    Slide 23: Projected Lung Cancer Market Entry & Revenue Model

    Projected Lung Cancer Market Entry & Revenue Model ACTIVITY MARKET REVENUE SOURCE TIMING VA L I D AT E M A R K E R S TA R G E T F O R I TA / L D T C E R T I F I C AT I O N AT CANADA-QUEBEC 2021/22 BIOMARK’S LAB IN QUEBEC USING NEW LDTD TECHNOLOGY PROVIDE TEST SERVICE FROM CANADA-QUEBEC  SALES OF LD

  24. Slide 24: Impending Catalyst – Short Terms

    Slide 24: Impending Catalyst – Short Terms

    Impending Catalyst – Short Terms Lung Cancer GBM – Leverage SSAT Platform Set operations in Quebec to accelerate Obtained Health Canada No Objection Letter for commercialization efforts. Secure soft landing GBM trials at CancerCare Manitoba. Patient support fund in 2021 recruitment underway. Study f

  25. Slide 25: BioMark Cap Table Summary

    Slide 25: BioMark Cap Table Summary

    BioMark Cap Table Summary • Trading Symbols: CSE: BUX / OTCMKTS: BMKDF / FSE: 20B • Common Shares Issued and Outstanding: 76,784,229 • Warrants (@ $0.20 & @ $0.45): 2,337,579 • Options (@ $0.15 - $0.30): 4,195,000 • Insiders ownership: 60% • Capital Raised (to-date): CAD $ 11 m 25

  26. Slide 26: Contact Details

    Slide 26: Contact Details

    Rashid Bux Contact Details rahmed@biomarkdiagnostics.com Rashid.biomark@gmail.com Office: 604-370-0779 Mobile:604-836-6950 www.biomarkdiagnostics.com A NEXT GENERATION COMPANY POWERED BY METABOLOMICS AND 26 ARTIFICIAL INTELLIGENCE

Source: Internet Archive copy of biomarkdiagnostics.com

More decks from BioMark Diagnostics, Inc.

All 7 BioMark Diagnostics decks